Indian Pharmaceutical Gets USFDA Approval to Market Hepatitis B Drug In The US

by Lakshmi Darshini on  August 28, 2015 at 6:10 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

The health regulators in the US approve Aurobindo Pharma to market generic Entecavir tablets, used to treat hepatitis B, in the American market.
Indian Pharmaceutical Gets USFDA Approval to Market Hepatitis B Drug In The US
Indian Pharmaceutical Gets USFDA Approval to Market Hepatitis B Drug In The US

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Entecavir tablets in strengths of 0.5mg and 1mg, Aurobindo Pharma said in a statement.

The Hyderabad-based firm's approved abbreviated new drug application (ANDA) is therapeutically equivalent to Bristol-Myers Squibb's Baraclude tablets. Entecavir tablets are indicated for treatment of chronic hepatitis B virus infection of the liver. According to IMS data, the product has an estimated market size of USD 294 million for the 12 months ending June 2015.

"This is the 44th ANDA to be approved out of Unit VII formulation facility in Hyderabad for manufacturing oral non-antibiotic products," the company said. The company has now a total of 209 ANDA approvals from the USFDA.

Source: PTI

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Hepatitis A Hepatitis B Hepatitis B Virus Signature Drug Toxicity Silent Killer Diseases Liver Aplastic Anemia HBV Screening Hepatitis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive